We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Aptose Biosciences Inc | TSX:APS | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.03 | -1.82% | 1.62 | 1.63 | 1.69 | 1.65 | 1.62 | 1.65 | 1,700 | 14:58:41 |
From May 2022 to May 2024
By Colin Kellaher
Aptose Biosciences Inc. on Wednesday said the U.S. Food and Drug Administration granted fast-track designation to HM43239 for the treatment of patients with relapsed or refractory acute myeloid leukemia with FLT3 mutation.
The Toronto clinical-stage oncology company is currently conducting a Phase 1/2 study of HM43239 in patients with the cancer of the blood and bone marrow.
The FDA's fast-track program is designed to facilitate the development and expedite the review of treatments for serious or potentially life-threatening illnesses with high unmet medical needs. The agency previously granted orphan-drug designation to HM43239 for treatment of acute myeloid leukemia in 2018.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 04, 2022 08:07 ET (12:07 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Aptose Biosciences Chart |
1 Month Aptose Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
